Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.55 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14026150 | 0.94 | CNR2 (0.55) | CNR2SYKMAOBGRM5PTK2 | |
| Formic Acid SCHEMBL4895900 | 0.89 | CNR2 (0.57) | CNR2SYKMAOBGRM5PTK2 | |
| Formic Acid SCHEMBL4886208 | 0.86 | CNR2 (0.57) | CNR2SYKCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14026161 | 0.85 | CNR2 (0.58) | CNR2SYKMAOBGRM5PTK2 | |
| SCHEMBL4892375 | 0.81 | CNR2 (0.52) | CNR2GRM5CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4893836 | 0.81 | CNR2 (0.63) | CNR2SYKMAOBGRM5PTK2 | |
| SCHEMBL14026122 | 0.80 | CNR2 (0.57) | CNR2SYKMAOBGRM5CYP3A4 | |
| Formic Acid SCHEMBL4896490 | 0.79 | CNR2 (0.51) | CNR2CYP3A4CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL4889009 | 0.79 | CNR2 (0.54) | CNR2SYKMAOBGRM5PTK2 | |
| SCHEMBL4897124 | 0.77 | CNR2 (0.62) | CNR2SYKMAOBGRM5PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | CNR2, CNR1, P2RY2 | CNR2 1/4885SYK 2878/4885MAOB 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.